Identification of broadly reactive DR restricted epitopes

Details Identification of broadly reactive DR restricted epitopes Identification of broadly reactive DR restricted epitopes

1998-01-21

2002-07-02

Stucker, Jeffrey (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S186100, C424S193100, C424S093100, C424S093200, C424S093210, C435S173300, C435S173300, C435S235100, C435S320100, C435S325000, C435S006120, C514S002600, C514S04400A, C514S015800, C530S300000, C530S332000, C530S327000, C530S868000, C536S023100, C536S023400, C536S023500, C536S023740

Reexamination Certificate

active

06413517

ABSTRACT:

BACKGROUND OF THE INVENTION
Helper T lymphocytes (HTL) play several important functions in immunity to pathogens. Firstly, they provide help for induction of both CTL and antibody responses. By both direct contact and by secreting lymphokines such as IL2 and IL4, HTL promote and support the expansion and differentiation of T and B cell precursors into effector cells. In addition, HTL can also be effectors in their own right, an activity also mediated by direct cell contact and secretion of lymphokines, such as IFN&ggr; and TNF&agr;. HTL have been shown to have direct effector activity in case of tumors, as well as viral, bacterial, parasitic, and fungal infections.
HTL recognize a complex formed between Class II MHC molecules and antigenic peptides, usually between 10 and 20 residues long, and with an average size of between 13 and 16 amino acids. Peptide-Class II interactions have been analyzed in detail, both at the structural and functional level, and peptide motifs specific for various human and mouse Class II molecules have been proposed.
In the last few years, epitope based vaccines have received considerable attention as a possible mean to develop novel prophylactic vaccines and immunotherapeutic strategies. Selection of appropriate T and B cell epitopes should allow to focus the immune system toward conserved epitopes of pathogens which are characterized by high sequence variability (such as HIV, HCV and Malaria).
In addition, focusing the immune response towards selected determinants could be of value in the case of various chronic viral diseases and cancer, where T cells directed against the immunodominant epitopes might have been inactivated while T cells specific for subdominant epitopes might have escaped T cell tolerance. The use of epitope based vaccines also allows to avoid “suppressive” T cell determinants which induce TH
2
responses, in conditions where a TH
1
response is desirable, or vice versa.
Finally, epitope based vaccines also offer the opportunity to include in the vaccine construct epitopes that have been engineered to modulate their potency, either by increasing MHC binding affinity, or by alteration of its TCR contact residues, or both. Inclusion of completely synthetic non-natural or generically unrelated to the pathogen epitopes (such as TT derived “universal” epitopes), also represents a possible mean of modulating the HTL response toward a TH
1
, or TH
2
phenotype.
Once appropriate epitope determinants have been defined, they can be assorted and delivered by various means, which include lipopeptides, viral delivery vectors, particles of viral or synthetic origin, naked or particle absorbed cDNA.
However, before appropriate epitopes can be defined, one major obstacle has to be overcome, namely the very high degree of polymorphism of the MHC molecules expressed in the human population. In fact, more than two hundred different types of HLA Class I and Class II molecules have already been identified. It has been demonstrated that in the case of HLA Class I molecules, peptides capable of binding several different HLA Class I molecules can be identified. Over 60% of the known HLA Class I molecules can, in fact, be grouped in four broad HLA supertypes, characterized by similar peptide binding specificities (HLA supermotifs).
In the case of Class III molecules, it is also known that peptides capable of binding multiple HLA types and of being immunogenic in the context of different HLA molecules do indeed exist. Until now, however, a general method for their identification has not been developed, probably at least in part a reflection of the fact that quantitative DR binding assays are labor intensive and that a large number of alleles [is?
eeds?] to be considered.
The present invention addresses these and other needs.
SUMMARY OF THE INVENTION
The present invention is based, at least in part, on the discovery and validation of specific motifs and assay systems for various DR molecules, representative of the worldwide population. Their application to the identification of broadly degenerate HLA Class II binding peptides is also described.
Definitions
The term “peptide” is used interchangeably with “oligopeptide” in the present specification to designate a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of adjacent amino acids. The oligopeptides of the invention are less than about 50 residues in length and usually consist of between about 10 and about 30 residues, more usually between about 12 and 25, and often 15 and about 20 residues.
An “immunogenic peptide” is a peptide which comprises an allele-specific motif such that the peptide will bind an MHC molecule and induce a HTL response. Immunogenic peptides of the invention are capable of binding to an appropriate HLA molecule and inducing HTL response against the antigen from which the immunogenic peptide is derived.
A “conserved residue” is a conserved amino acid occupying a particular position in a peptide motif typically one where the MHC structure may provide a contact point with the immunogenic peptide. One to three, typically two, conserved residues within a peptide of defined length defines a motif for an immunogenic peptide. These residues are typically in close contact with the peptide binding groove, with their side chains buried in specific pockets of the groove itself.
The term “motif” refers to the pattern of residues of defined length, usually between about 8 to about 11 amino acids, which is recognized by a particular MHC allele.
The term “supermotif” refers to motifs that, when present in an immunogenic peptide, allow the peptide to bind more than one HLA antigen. The supermotif preferably is recognized by at least one HLA allele having a wide distribution in the human population, preferably recognized by at least two alleles, more preferably recognized by at least three alleles, and most preferably recognized by more than three alleles.
The phrases “isolated” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the peptides of this invention do not contain materials normally associated with their in situ environment, e.g., MHC I molecules on antigen presenting cells. Even where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated peptides of this invention do not contain such endogenous co-purified protein.
The term “residue” refers to an amino acid or amino acid mimetic incorporated in an oligopeptide by an amide bond or amide bond mimetic.


REFERENCES:
patent: 5736142 (1998-04-01), Sette et al.
patent: 5880103 (1999-03-01), Urban et al.
patent: WO 92/02543 (1992-02-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 93/20103 (1993-10-01), None
patent: WO94/03205 (1994-02-01), None
patent: WO 94/11738 (1994-05-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO 95/25122 (1995-09-01), None
patent: WO 95/26982 (1995-10-01), None
Bowie et al. p. 1306; p. 1308, 1990.*
Rammensee et al, Immunogenetics; 41, 178-228, 1995.*
Marshall et al , Journal of Immunology 154; 5927-5933, 1995.*
Houghten et al, Vaccines 86; 21-25, 1986.*
Sinigaglia and Hammer Curr.Opin.Immunol 6; 52-56, 1994.*
J. Alexander et al.,Immunity(1994) 1: 751-761.
R. Busch et al.,International Immunology(1990) 2(5): 443-451.
K. Falk et al.,Immunogenetics(1994) 39: 230-242.
A. Geluk et al.,Journal of Immunology(1994) 152: 5742-5748.
J. Hammer et al.,J. Exp. Med.(1994) 180: 2353-2358.
C.M. Hill et al.,Journal of Immunology(1994) 152: 2890-2898.
T.S. Jardetzky et al.,The EMBO Journal(1990) 9(6): 1797-1803.
J.I. Krieger et al.,Journal of Immunology(1991) 146: 2331-2340.
K.W. Marshall et al.,Journal of Immunology(1995) 154: 5927-5933.
D. O'Sullivan et al.,Journal of Immunology(1990) 145: 1799-1808.
D. O'Sullivan et al.,Journal of Immunology(1991) 146:

Affiliated with

Also associated with

Rating

Identification of broadly reactive DR restricted epitopes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Identification of broadly reactive DR restricted epitopes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of broadly reactive DR restricted epitopes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2913377